JSLS : Journal of the Society of Laparoendoscopic Surgeons · 2025
Efficacy of Endoscopic Isolated Papillary Small Balloon Dilation for Treating Choledocholithiasis.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shen Junsong, Wang Xiang, Zhang Lili, Cheng Fenggan
Аннотация
OBJECTIVE: The current study aimed to compare clinical outcomes and postoperative complications of two endoscopic treatments (endoscopic isolated papillary small balloon dilation [EIPSBD] and endoscopic sphincterotomy [EST]) with endoscopic papillary balloon dilation (EPBD) in patients with choledocholithiasis.
METHODS: A total of 316 patients diagnosed with and treated for choledocholithiasis from January 2014 to December 2024 were enrolled in this nonrandomized study. The patients were divided into EIPSBD (n = 178) and EST + EPBD groups (n = 138). Postoperative morbidities, including pancreatitis, cholangitis, bleeding, and hyperamylasemia, were assessed at 3 and 24 hours. Stone clearance was also evaluated.
RESULTS: The incidence of pancreatitis was 9.55% in the EIPSBD group and 7.97% in the EST + EPBD group (P = .5). Hyperamylasemia occurred in 41.57% of the patients in the EIPSBD group and 42.03% in the EST + EPBD group (P = .9). The incidence of cholangitis, bleeding, and stone clearance was not significantly different between the two groups. The incidence of pancreatitis in female patients was greater than male patients (χ2 = 5.12, P = .025). The total complication rate was 10.67% and 10.14% in the EIPSBD and EST ± EPBD groups, respectively, and was not significantly different (P = .9).
CONCLUSION: EIPSBD and EST ± EPBD were shown to be equally effective in the treatment of choledocholithiasis with comparable postoperative complication rates. EIPSBD may be an acceptable alternative to traditional EST for stones ≤10 mm in size. Follow-up studies of longer duration will be helpful to assess long-term outcomes.
METHODS: A total of 316 patients diagnosed with and treated for choledocholithiasis from January 2014 to December 2024 were enrolled in this nonrandomized study. The patients were divided into EIPSBD (n = 178) and EST + EPBD groups (n = 138). Postoperative morbidities, including pancreatitis, cholangitis, bleeding, and hyperamylasemia, were assessed at 3 and 24 hours. Stone clearance was also evaluated.
RESULTS: The incidence of pancreatitis was 9.55% in the EIPSBD group and 7.97% in the EST + EPBD group (P = .5). Hyperamylasemia occurred in 41.57% of the patients in the EIPSBD group and 42.03% in the EST + EPBD group (P = .9). The incidence of cholangitis, bleeding, and stone clearance was not significantly different between the two groups. The incidence of pancreatitis in female patients was greater than male patients (χ2 = 5.12, P = .025). The total complication rate was 10.67% and 10.14% in the EIPSBD and EST ± EPBD groups, respectively, and was not significantly different (P = .9).
CONCLUSION: EIPSBD and EST ± EPBD were shown to be equally effective in the treatment of choledocholithiasis with comparable postoperative complication rates. EIPSBD may be an acceptable alternative to traditional EST for stones ≤10 mm in size. Follow-up studies of longer duration will be helpful to assess long-term outcomes.